enGene (NASDAQ:ENGN – Get Free Report) and Onconetix (NASDAQ:ONCO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Earnings & Valuation
This table compares enGene and Onconetix”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| enGene | N/A | N/A | -$117.30 million | ($2.17) | -0.90 |
| Onconetix | $810,000.00 | 3.13 | -$14.03 million | $248.12 | 0.00 |
Risk & Volatility
enGene has a beta of -0.28, suggesting that its stock price is 128% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 2.69, suggesting that its stock price is 169% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for enGene and Onconetix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| enGene | 2 | 8 | 4 | 0 | 2.14 |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
enGene presently has a consensus price target of $11.05, suggesting a potential upside of 466.43%. Given enGene’s stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than Onconetix.
Insider & Institutional Ownership
64.2% of enGene shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Comparatively, 0.3% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares enGene and Onconetix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| enGene | N/A | -56.06% | -45.64% |
| Onconetix | -1,575.89% | -91.95% | -53.76% |
Summary
enGene beats Onconetix on 8 of the 13 factors compared between the two stocks.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
